Under the leadership of Jared Tangney and Josh Windmiller, Biolinq is redefining how biomedical innovations can be imagined and commercialized. While conducting his post-doctoral research at the University of California, San Diego in the laboratory for NanoBioElectronics, Josh saw the potential to bring nanotechnology to the medical world. Combining forces with Jared, a PhD in Biomedical Engineering, the two saw the opportunity to bring their minimally-invasive technology to the diabetes space. Finally, people with diabetes will have a better CGM experience that is not only more affordable, but also pain-free.
THE NEXT GENERATION OF CONTINUOUS GLUCOSE MONITORING WILL BENEEDLE FREE.
Bringing the next generation CGM technology to market requires brilliant expertise and focused leadership, along with the ability to deliver miniaturized technology with unparalleled performance. Leveraging ground breaking research at UC San Diego, Biolinq’s intradermal CGM allows for a pain-free means to sense glucose. Combined with advances in scalable manufacturing techniques, the stage is set for disruption in an exploding market.
OUR VISION: APPLICATION WITH THE PRESS OF A THUMB
While we cannot remove all the struggles of diabetes, we believe the pain and hassle of needle-based approaches to CGM should be relegated to technology of yesteryear. By removing the need to get under the skin, Biolinq’s minimally-invasive technology is pain-free both during application as well as throughout everyday wear.
Today we are focused on glucose monitoring, but we have built a platform capable of much more. Imagine having access to dozens of biomarkers at a time, without drawing a drop of blood. The possibilities are endless.
What would you like to measure?